PY8012 - PHARMACOGENOMICS (Syllabus) 2017-regulation Anna University

PY8012 - PHARMACOGENOMICS (Syllabus) 2017-regulation Anna University

PY8012	PHARMACOGENOMICS	LPTC

3003

OBJECTIVES:

• The course intends to provide knowledge about pharmacogenomics and drug design using genomic applications for drug action and toxicity.
• To understand how individualization of drug therapy can be achieved based on a person’s genetic makeup while reducing unwanted drug effects.

UNIT I	PHARMACOGENOMICS AND PERSONALIZED MEDICINE	9

Pharmacogenetics- Roots of pharmacogenomics and it is not just pharmacogenomics, Genetic drug response profiles, the effect of drugs on Gene expression, pharmacogenomics in drug discovery and drug development. Concept of individualized drug therapy, Drivers and the promise of personalized medicine, Strategies for application of pharmacogenomics to customize therapy, Barriers.

UNIT II	HUMAN GENOME	9

Expressed sequence Tags (EST) and computational biology, Microbial genomics, computational analysis of whole genomes, computational genome analysis, Genomic differences that affect the outcome of host pathogen interactions, Protein coding genes, repeat elements, genome duplication, analysis of proteome, DNA variation, Biological complexity. Single nucleotide polymorphisms (SNP’s) in Pharmacogenomics - approaches, number and types of SNPs, Study design for analysis, Analytical issues, Development of markers.

UNIT III	ASSOCIATION STUDIES IN PHARMACOGENOMICS	9

Viability and Adverse drug reaction in drug response, Multiple inherited genetic factors influence the outcome of drug treatments, Association studies in pharmacogenomics, Strategies for pharmacogenomics Association studies, Benefits of Pharmacogenomics in Drug R & D.

UNIT IV	GENOMICS APPLICATIONS FOR DRUG ACTION, TOXICITY AND DESIGN	9

Platform technologies and Pharmaceutical process, its applications to the pharmaceutical industry, Understanding biology and diseases, Target identification and validation, Drug candidate identification and optimization, safety and toxicology studies. The need of protein structure information, protein structure and variation in drug targets-the scale of problem, Mutation of drug targets leading to change in the ligand binding pocket.

UNIT V	PHARMACOGENOMICS – CASE STUDIES	9

Study of pharmacogenomics of human P-Glycoprotein, drug transporters, lipid lowering drugs, chemotherapeutic agents for cancer treatment.

TOTAL : 45 PERIODS

OUTCOMES: At the completion of course, the student will be able to

• Distinguish the effect of genetic differences between individuals in the outcome of drug therapy and in drug efficacy and toxicity.
• Describe the role of single nucleotide polymorphism as a biomarker for the prediction of risk, therapeutic response and prognosis of malignancies.
• Utilize and manage the new genomics based tools as they become available as well as make best treatment choices.

TEXT BOOKS:

1. Martin M. Zdanowicz, M.M. “Concepts in Pharmacogenomics” Second Edition, American Society of Health-System Pharmacists, 2017.
2. Licinio, J and Wong, Ma-Li. “Pharmacogenomics: The Search for the Individualized Therapies”, Wiley-Blackwell, 2009.
3. Yan Q, “Pharmacogenomics in Drug Discovery and Development” Humana Press, 2nd Edition, 2014.

REFERENCES:

1. Brazeau, D.A. and Brazeau, G.A. “Principles of the Human Genome and Pharmacogenomics” American Pharmacist Association, 2011
2. Werner, K., Meyer, U.A., Tyndale, R.F. “Pharmacogenomics”, Second Edition, Taylor and Francis, 2005.
3. Langman, L.J. and Dasgupta, A. "Pharmacogenomics in Clinical Therapeutics", Wiley – Blackwell, 2012